A5026699354- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Genetic factors in colorectal cancer
- Glioma Diagnosis and Treatment
- Ovarian cancer diagnosis and treatment
- Brain Metastases and Treatment
- Cancer Genomics and Diagnostics
- PI3K/AKT/mTOR signaling in cancer
- Breast Cancer Treatment Studies
- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers
- PARP inhibition in cancer therapy
- Colorectal and Anal Carcinomas
- Lung Cancer Research Studies
- Cancer-related Molecular Pathways
- Chronic Lymphocytic Leukemia Research
- Peptidase Inhibition and Analysis
- Testicular diseases and treatments
- Endometrial and Cervical Cancer Treatments
- Monoclonal and Polyclonal Antibodies Research
- BRCA gene mutations in cancer
- Colorectal Cancer Treatments and Studies
- Reproductive Biology and Fertility
- Multiple and Secondary Primary Cancers
Institut de Cancérologie de l'Ouest
2016-2025
Roche (Switzerland)
2021
Centre Hospitalier Universitaire de Rennes
2019
Centre Jean Perrin
2013-2019
Centre Eugène Marquis
2018-2019
Centre Hospitalier Universitaire de Nantes
2018-2019
Centre Hospitalier Départemental Vendée
2019
Roche (France)
2018-2019
Centre Hospitalier Universitaire de Limoges
2019
Centre Hospitalier Universitaire de Clermont-Ferrand
2019
Abstract Background Metastatic breast cancer (MBC) behaviour differs depending on hormone receptors (HR) and human epidermal growth factor receptor (HER2) statuses. Methods The kinetics of central nervous system (CNS) metastases (CNS metastasis-free survival, CNSM-FS) subsequent patient’s prognosis (overall OS) according to the molecular subtype were retrospectively assessed in 16703 MBC patients ESME nationwide multicentre database (Kaplan–Meier method). Results CNS occurred 4118 (24.6%)...
We proposed in 2005 that androgens replace oestrogens as the driver steroids a subgroup of triple-negative breast cancer (TNBC) with androgen receptor (AR) expression called molecular apocrine (MA) or luminal (LAR). Here, we report analysis clinical trial evaluating antitumour activity anti-androgen darolutamide MA cancer. Our aim was to assess benefit patients AR-positive TNBCs defined by immunohistochemistry and RNA profiling. In this multicentre, non-comparative, randomised, phase 2...
Abstract Missense mutations in the polymerase epsilon (POLE) gene have been reported to generate proofreading defects resulting an ultramutated genome and sensitize tumors checkpoint blockade immunotherapy. However, many POLE-mutated do not respond such treatment. To better understand link between POLE mutation variants response immunotherapy, we prospectively assessed efficacy of nivolumab a multicenter clinical trial patients bearing advanced mismatch repair–proficient solid tumors. We...
<h3>Importance</h3> Endometrial cancer is often hormone-dependent and treated with aromatase inhibitors. The PI3K-AKT-mTOR pathway deregulation observed in endometrial drives hormonal resistance, thus supporting the rationale of combining mTOR inhibitor endocrine therapy. <h3>Objective</h3> To evaluate safety efficacy vistusertib combination anastrozole treatment women hormone receptor−positive recurrent or metastatic cancer. <h3>Design, Settings, Participants</h3> VICTORIA study was a...
Purpose: Investigates the link between HER2 status and histological response after neoadjuvant chemotherapy in patients with early TNBC. Methods: We retrieved clinical anatomopathological data retrospectively from 449 treated for first time standard unilateral BC 2005 2020. The primary endpoint was pathological complete (pCR, i.e., ypT0 ypN0), according to status. Secondary endpoints included invasive disease-free survival (I-DFS) overall (OS). Results: 437 were included, 121 (27.7%) had...
Leptomeningeal metastasis (LM) is a rare complication of metastatic breast cancer (MBC), with high morbidity/mortality rates. Our study aimed to describe the largest-to-date real-life population MBC patients treated intrathecal (IT) therapy and evaluate prognostic models.The Epidemiological Strategy Medical Economics (ESME) database (NCT03275311) includes all consecutive who have initiated treatment for since 2008. Overall survival (OS) IT was estimated using Kaplan-Meier method. Prognostic...
Everolimus is the first oral targeted therapy widely used in advanced HR+/HER2− breast cancer. We sought to evaluate impact of everolimus-based on overall survival ESME-MBC database, a national metastatic cancer cohort that collects retrospective data using clinical trial-like methodology including quality assessments. compared 1693 patients having received everolimus 5928 not exposed same period. Overall was evaluated according treatment line, and propensity score with inverse probability...
Oncogenic FGFR-TACC fusions are present in 3-5% of high-grade gliomas (HGGs). Fexagratinib (AZD4547) is an oral FGFR1-3 inhibitor with preclinical activity FGFR-TACC+ gliomas. We tested its safety and efficacy patients recurrent + HGGs.
The interim analysis of the phase IIIb LUCY trial demonstrated clinical effectiveness olaparib in patients with germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (mBC), median progression-free survival (PFS) 8.11 months, which was similar to that arm III OlympiAD (7.03 months). This prespecified provides final overall (OS) and safety data.
Pazopanib (PZB), an anti-angiogenic tyrosine kinase inhibitor, has shown activity in pre-treated advanced glioblastomas (GBM). Biological and clinical data support the evaluation of PZB earlier stage disease. The objective PAZOGLIO trial (NCT02331498) is to evaluate safety (phase I) efficacy II) combined with Temozolomide (TMZ) during maintenance phase as defined by "Stupp protocol" GBM patients after complete or partial resection surgery. Here, we report updated results I. a prospective...
Abstract Purpose Previous studies have reported the benefit of dual HER2-targeting combined to neoadjuvant chemotherapy in HER2-amplified breast cancer (HER2 + BC). Moreover, besides cardiac toxicity following their association Trastuzumab, anthracyclines may not profit all patients. The NeoTOP study was designed evaluate complementary action Trastuzumab and Pertuzumab, relevance an anthracycline-based regimen according TOP2A amplification status. Methods Open-label, multicentre, phase II...